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Mamane: Scientific Therapy for 
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Douglas G. Massey MD,** Yu Kun Chien MD,t 
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Mortality from asthma in Hawaii continues to increase and 
chronic problems of medication compliance, side effects, and 
cost persist. The advisability of adding alternative (traditional) 
medication for its anti-inflammatory and anti-allergic function 
was examined. One of the herbs for asthma in the Hawaiian 
narrative tradition is mamane, or in scientific terminology, Sophora 
chrysophyl/a. The scientific literature on S. chrysophyl/a and of 
the closely related species Sophora flavescens ait were re-
viewed in this context and the findings support further investiga-
tion. 
Introduction 
Mortality from asthma has increased in Hawaii since the 1980s 
and still shows no consistent decline. 1 Furthermore, compliance 
with therapy, drug side effects, and costs continue to be chronic 
problems. To determine the potential contribution of alternate 
medicine to their resolution, a historical review of written and 
traditional narrated Hawaiian materia medica for asthma was 
conducted and 58 herbs were selected as being potentially useful 
therapeutically.2 Among these was mamane or Sophora 
chrysophylla. 
We selected S. chrysophylla for a scientific literature review 
of its role in asthma. In addition to its local use, the genus 
Sophora has been a source of alternative medication for centu-
ries for people from India to America? The structurally similar 
Sophoraflavescens ait (SFA) has extensive scientific literature. 
Methods 
The scientific literature was searched under the headings of 
mamane and of S. chrysophylla. Subsequently, the search cen-
tered on the scientific bibliography of the closely related species, 
Sophoraflavescens ait. 
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Results 
Botany 
Leguminosae or the pea family is the third-largest family of 
flowering plants, consisting of some 600 genera and 17,000 
species.4 It has 3 subfamilies, one of which is Papilionatae, and 
it contains the genus Sophora. Among the 50 or so species of 
Sophora areS. chrysophylla and the closely related SF A. The 
former is endemic to Hawaii,5 and the latter is found in China.6a 
The growth of mamane varies from a shrub at low altitudes to 
a tree 2 feet in diameter and 40 feet tall at high altitudes. 7 It is 
widespread except on the island of Molokai. Optimal growing 
conditions include sunny slopes, heavy rainfall, and strong 
winds. 
Although flowers, leaves, seeds and bark have medicinal 
properties, the root is the portion used most frequently; it is 
believed to be best harvested with appropriate religious ceremo-
nies. 
Chemistry 
A century ago, chemists investigated the subfamily 
Papilionatae because of its poisonous side effects when used as 
cattle fodder, as applications in veterinary medicine, and as 
insecticides. 8 The major components are alkaloids with some 
flavonoids, glycoproteins, and chromones.6a·9 
Alkaloids are nitrogen-containing compounds widely used 
medicinally. The alkaloidal content and structure of S. 
chrysophylla have been investigated.8•10- 13 Among these were 
anagyrine, cytisine, mamanine, matrine, pohakuline, 
sophochrysine, and sophoramine. Major alkaloids of the closely 
related species, SFA, are anagyrine, baptifoline, cytisine, matrine, 
N-methylcytisine, oxymatrine, sophocarpine, sophoramine, and 
sophoranol. 14 Their biogenesis has been extensively studied 
with isotope tracers. 
Quantitatively and qualitatively matrine, or C15H24N20, is the 
major alkaloid of these 2 species. Attention also is drawn to 
oxymatrine, C15H24N20 2, which is structurally almost identical 
and has the same solubility profile.6a Matrine is easily oxidized 
by H20 2 to oxymatrine which, in tum, is reduced to matrine by 
hydrogen. The extensive international research literature on 
oxymatrine may be applicable to matrine. 
Absorption, fate, and excretion 
S. chrysophylla is traditionally administered either as a tea or 
topically 15 and other Sophoras are available in the form of 
tablets, aerosols, and intramuscular and intravenous prepara-
tions. 3 No data is available on the metabolism of S. chrysophylla, 
but research has been published on those components it shares 
-
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with the closely related Sophora species. 
Oral matrine was absorbed in rats and mice and was widely 
distributed in tissues with selective concentration in the lungs; 
for this reason, matrine may be more suitable than other alka-
loids of Sophora in the therapy of asthma. 16 In rats, 80.1% of 
ingested matrine was excreted in the urine in less than 24 hours, 
and in humans, 60%. 
Oxymatrine was metabolized somewhat differently than 
matrine, depending on the route of administration. Oral 
oxymatrine was transformed to matrine in the gastrointestinal 
tract of rats and mice, which explains why the concentration of 
matrine was higher than oxymatrine in the tissues. By 24 hours, 
80% of the oxymatrine ingested was excreted, more as matrine 
than oxymatrine. 16 In 3 humans who took 380 ).1M of oxymatrine 
orally at night, the total combined matrine and oxymatrine found 
in the urine in 24 hours was 41. I%, 43.2%, and 70.1 %, respec-
tively, and of these 67.1%, 61.1%, and 53.1% was matrine. 16 
When given intramuscularly, oxymatrine concentration was 
high in tissue, bile, and urine with 85.3% of the total dose being 
excreted unchanged in the urine in 24 hours. 16 Intravenous 
oxymatrine in rats disappeared rapidly from the plasma with the 
plasma concentration versus time following a 2-compartment 
model: T 112 (a)= 5.8 min and T 112 (B)= 27.0 min. 16 There was 
no prolongation of the half-life or elimination by increasing the 
dose by 25, 50, or 100 mg/kg intravenously. In a similar study 
in rabbits, oxymatrine was given intravenously as 25, 50, od 00 
mg/kg. 17 The plasma concentration-time curves again fitted the 
2-compartment model of 5.8 and 29.6 min respectively and 
pharmacokinetic parameters a and b were not changed with 
variable drug doses. Excretion was renal with little or none in the 
feces or bile. 
Pharmacology 
Bronchodilator.-Sophora alkaloids have an antiasthmatic 
effect.3 As with theophylline, Sophora has influenced the activ-
ity of adenylate cyclase or phosphodiesterase, 18 but findings by 
Y.K. Chien in 1992 noted that the cAMP level remained stable 
with oxymatrine therapy and did not confirm in vitro a phos-
phodiesterase effect, at least with this alkaloid. 
S. japonica agglutinin labeled the small mast cells but not the 
large 19 perhaps indicating a selective action of Sophoras on 
bronchodilation. 
Anti-inflammatory.-The importance of inflammation in 
asthma has been stressed recently. Management of this chronic 
inflammation is difficult even with anti-inflammatory drugs 
such as steroids, methotrexate, and gold salts because of toxic-
ity. The benign anti-inflammatory action of Sophoras could be 
utilized. There is extensive evidence of this function. 20. 21 An 
effect of SF A was modification of interleukin-1 and interleukin-
6 of inflammatory asthma. 
Anti-allergy.-Matrine and oxymatrine have major anti-
allergic actions. Using a model of immediate hypersensitivity in 
the guinea pig, oxymatrine decreased mortality to 61% and 
suppressed the IgE response (p<0.01) after a week of treat-
ment.22-23 
Histamine release from mouse peritoneal mast cells was 
suppressed by oxymatrine when it was induced by allergic 
stimulants anti-DNP IgE, and TNP-KLH, but not by non-
allergic stimulants such as PMA, A23187, or ATP. 24 Oxymatrine 
might interfere with histamine release by stabilizing the mast 
cell membrane and decreasing its fluidity in a dose-dependent 
manner. 
Immune response.-In 15 patients with severe asthma, 50% 
purified SF A administered over 2 months lowered IgE, but not 
-
IgA or IgG, and increased interleukin-1 and -4. 
According to the Y .K. Chien, eta!. studies, the concentration 
of Sophoras is a major determinate of their action on the immune 
system. Using lymphocyte numbers and interleukin levels as 
markers in mice, oxymatrine stimulated the immune system at 
low concentrations ( 1 o-s to 1 0·2) and suppressed it at higher 
concentrations (> 1.0 mg/ml). 
Among actions gleaned from the literature, SF A alkaloids 
inhibited antibody production in sensitized animals and de-
pressed their skin reaction. Matrine inhibited the phagocytic 
function of mouse peritoneal macrophages in vitro. 19 Also, 
oxymatrine inhibits B but not T Iymphocytes. 19•24 
Antibiotic.-Infection is a frequent trigger of asthma, and 
antibiotics are important for prophylaxis and for treating epi-
sodes. A 1% solution of matrine inhibited in vitro growth of such 
organisms as Bacillus dysenteriae, Escherichia coli, Bacillus 
proteus,j3- streptococcus, and Staphlococcus au reus. SFA solu-
tion inhibited violet mycelial fungus, several skin fungi, 
trichomonas, and influenced flagellae. 25 
Toxicity and Precautions.-After centuries of use, very little 
toxicity has been linked to S. chrysophylla or to SFA. 6b Unlike 
allopathic medicine where the purity of a drug is paramount, 
alternative medication consists of a number of components that 
display a balance between active constituents and those that 
buffer the side effects. Thus, a desiccated root has few side 
effects, extracts have more, and purified products can rarely be 
seriously toxic.3 
Of importance in asthma are the rare reports of presumed 
respiratory dysfunction. Matrine has been associated with respi-
ratory center depression in animals, but the results are variable. 6b 
When administered into rabbit ears intravenously, matrine up to 
0.036 mg/kg was safe, 0.045 to 0.10 mg/kg led to weakness, 0.10 
to 0.11 mg/kg could lead to failure with a partial recovery, but 
0.133 mg/ kg led to signs off ear, limb weakness and spasm, and 
a respiratory death. In another study, the LD50 of intravenous 
matrineinrabbits was 125 mg/kg.6binmice, it was 150mg/kg.6b 
Oxymatrine showed an LD50 with 150 mg/kg intravenously given to mice and 750 mg/kg intra-peritoneally.6b Another study 
foundvaluesof952.6± 11.6mg/kgand519± 15.18mg/kgintra-
peritoneally, respectively.6b The LD50 for acute toxicity in mice 
was 256.74 ± 57.36 mg/kg and intravenously was 144.2 ± 22.8/ 
kg according to personal communication with Y. Y. Chen, 
Professor of Pharmacology at the Beijing Medical University in 
1992. 
Sophocarpine, another alkaloid, might slow respiration and 
decrease blood pressure when injected intra-peritoneally in 
rabbits in large doses, ie, up to 150 mg/kg or 78 ± 1.6 mg/kg.6b 
In tests of mutagenicity, Yin found that SF A induced chromo-
somal aberration in Salmonella typhimurium26 but this was not 
confirmed by Chen. 
Clinical Applications 
No controlled trials of Sophora in asthma or infective asthma 
have been published in Western medical literature. The Anti-
asthma Drug Research Group, Department of Pharmacology at 
Guiyang Medical College reported that alkaloids of SFA used to 
treat 87 cases of chronic asthmatic bronchitis and 37 cases of 
bronchial asthma led to 90.3% success. Antitussive and expec-
torant actions were noted. A controlled, double-blind study was 
performed over 3 months in 15 severe asthmatics with 50% 
purified SFA. There was clinical improvement with increased 
tolerance to methacholine bronchial challenge, decreased use of 
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steroids, a drop in IgE, and alteration to interleukins. The SF A 
was cost-effective compared to the pretrial use of medication. 
Conclusions 
Among the herbal therapies for asthma used in Hawaii for 
centuries is mamane, or S. chrysophylla. It has the potential for 
excellent patient compliance, clinical improvement, and few 
side effects at a low cost. A review of the known scientific facts 
of this medication supplemented by those of the closely related 
species, SF A , suggests that mamane should be further assessed. 
An extract of the root of S. chrysophylla of research quality 
should be prepared for suitable scientific research. 
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